A double-blind placebo-controlled study of controlled release fluvoxamine for the treatment of generalized social anxiety disorder / H.G.M. Westenberg en Journal of Clinical Psychopharmacology, Año 2004 - Vol. 24 - No. 1 (Febrero)

Público ISBD [artículo]  inJournal of Clinical Psychopharmacology > Año 2004 - Vol. 24 - No. 1 (Febrero) . - pp. 49-55 Título : A double-blind placebo-controlled study of controlled release fluvoxamine for the treatment of generalized social anxiety disorder Tipo de documento: texto impreso Autores: H.G.M. Westenberg, Autor ; Dan J. Stein, Autor ; Haichen Yang, Autor Fecha de publicación: 2023 Artículo en la página: pp. 49-55 Idioma : Inglés (eng) Idioma original : Inglés (eng) Palabras clave: Trastornos de ansiedad, Preparados de acción retardada, Preparaciones de acción retardada, Fluvoxamina. Resumen: This was a randomized double-blind placebo-controlled multicenter study to assess the efficacy, safety, and tolerability of fluvoxamine in a controlled release (CR) formulation for treatment of generalized social anxiety disorder (GSAD). A total of 300 subjects with GSAD were randomly assigned to receive either fluvoxamine CR (N = 149) or placebo (N = 151) for 12 weeks. Link: ./index.php?lvl=notice_display&id=30978 [artículo] A double-blind placebo-controlled study of controlled release fluvoxamine for the treatment of generalized social anxiety disorder [texto impreso] / H.G.M. Westenberg, Autor ; Dan J. Stein, Autor ; Haichen Yang, Autor . - 2023 . - pp. 49-55. Idioma : Inglés (eng) Idioma original : Inglés (eng) in Journal of Clinical Psychopharmacology > Año 2004 - Vol. 24 - No. 1 (Febrero) . - pp. 49-55 Palabras clave: Trastornos de ansiedad, Preparados de acción retardada, Preparaciones de acción retardada, Fluvoxamina. Resumen: This was a randomized double-blind placebo-controlled multicenter study to assess the efficacy, safety, and tolerability of fluvoxamine in a controlled release (CR) formulation for treatment of generalized social anxiety disorder (GSAD). A total of 300 subjects with GSAD were randomly assigned to receive either fluvoxamine CR (N = 149) or placebo (N = 151) for 12 weeks. Link: ./index.php?lvl=notice_display&id=30978

---

1 (1 - 1 / 1)